Drug or treatment

Trametinib clinical trials

• 18Clinical trials
• 26Countries

Newest trials

All recruiting trials (18)

• Trametinib for Ras/MAPK Pathway Vascular Anomalies in Kids and Teens

  This study tests whether trametinib can help children and young people with Ras/MAPK-driven vascular anomalies.

  Recruiting Phase 2 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT07549646

• Gefitinib, trametinib, disulfiram, and sunitinib added to standard chemotherapy for metastatic osteosarcoma

  This study tests whether adding gefitinib, trametinib, disulfiram, and sunitinib to standard chemotherapy helps people with newly diagnosed metastatic osteosarcoma.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07477457

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

• Dabrafenib and trametinib dose-reduction for BRAF V600 low-grade glioma

  This trial tries to see if stopping or slowly lowering dabrafenib and trametinib after about 12–24 months works for people with BRAF V600–mutant low-grade glioma.

  Recruiting at 12 sites Phase 2 University of California, San Francisco · Birmingham, Alabama and 11 other locations · NCT07110246

• Dabrafenib or Trametinib plus Clofarabine for high-risk or relapsed pediatric Langerhans cell histiocytosis

  This treatment will test whether adding a MAPK inhibitor (dabrafenib or trametinib) to the chemotherapy drug clofarabine helps children and teens (0–18) with high-risk, recurrent, or refractory Langerhans cell histiocytosis.

  Recruiting Phase 2 West China Second University Hospital · Chengdu, Sichuan · NCT07022834

• Combining Imatinib and Trametinib for KRAS-mutated Solid Tumors

  This study tests if combining two cancer drugs, imatinib and trametinib, can help people with hard-to-treat solid tumors that have KRAS mutations.

  Recruiting Phase 1 China Medical University Hospital · Taichung, Taichung · NCT06962254

• Targeted treatment for Langerhans Cell Histiocytosis using trametinib

  This study is testing if trametinib, a new targeted therapy, can help children with Langerhans Cell Histiocytosis feel better and avoid the harsh side effects of traditional chemotherapy.

  Recruiting Phase 2 Cook Children's Health Care System · Fort Worth, Texas · NCT06582745

• Monitoring the use of Tafinlar and Mekinist in patients with specific tumors

  This study is testing how well the drugs Tafinlar and Mekinist work and how safe they are for adults and kids with certain hard-to-treat tumors.

  Recruiting at 39 sites Novartis · Nagakute, Aichi-ken and 69 other locations · NCT06262919

• Combining GNS561 and Trametinib for Advanced Cholangiocarcinoma with KRAS Mutation

  This study is testing if a new combination of two drugs, GNS561 and trametinib, can help people with advanced bile duct cancer and a specific gene mutation who haven't had success with standard treatments.

  Recruiting at 9 sites Phase 1/2 Genfit · Los Angeles, California and 10 other locations · NCT05874414

• Evaluating Dabrafenib and Trametinib for Rare BRAF V600E Mutation-Positive Tumors

  This study tests if the medications dabrafenib and trametinib can help people aged 6 and older with rare tumors that have a specific BRAF mutation.

  Recruiting at 8 sites Novartis · Torrance, California and 7 other locations · NCT05868629

• Combining trametinib and azacitidine for treating juvenile myelomonocytic leukemia

  This study is testing a new combination of medications to see if they can safely help children with juvenile myelomonocytic leukemia feel better, depending on their risk level.

  Recruiting at 21 sites Phase 1/2 Therapeutic Advances in Childhood Leukemia Consortium · Phoenix, Arizona and 20 other locations · NCT05849662

• Combination treatment for children with relapsed or refractory blood cancers

  This study is testing a new combination of medications to see if it can help children and young adults with tough-to-treat blood cancers feel better and improve their chances of recovery.

  Recruiting at 5 sites Phase 1/2 Princess Maxima Center for Pediatric Oncology · Vienna and 35 other locations · NCT05658640

• Treatment for BRAF mutated papillary craniopharyngioma

  This study is testing if a combination of two medications can help shrink tumors in patients with a specific type of brain tumor before they have surgery.

  Recruiting Phase 2 Skane University Hospital · Lund · NCT05525273

• Comparing a MEK inhibitor to chemotherapy for pediatric low-grade glioma

  This study is testing whether a new drug called trametinib works better than standard chemotherapy for children and young adults with low-grade brain tumors that have specific genetic features.

  Recruiting at 13 sites Phase 2 University Hospital, Strasbourg, France · Amiens and 24 other locations · NCT05180825

• Combining nilotinib with other drugs for treating metastatic melanoma

  This study is testing if adding nilotinib to existing treatments can help people with advanced melanoma that has a specific genetic mutation feel better and tolerate the drugs well.

  Recruiting at 3 sites Phase 1 University of Kentucky · Iowa City, Iowa and 3 other locations · NCT04903119

• Combination treatment for advanced solid tumors using Trametinib, Everolimus, and Lenvatinib

  This study is testing a new combination of three drugs to see if it can help people with advanced solid tumors, like liver cancer, feel better and improve their condition.

  Recruiting Phase 2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT04803318

• Using trametinib and everolimus to treat recurrent gliomas in children and young adults

  This study is testing a combination of two drugs, trametinib and everolimus, to see if they can safely help children and young adults with recurring brain tumors feel better and improve their quality of life.

  Recruiting at 15 sites Phase 1 University of California, San Francisco · Birmingham, Alabama and 16 other locations · NCT04485559

• Access to continued treatment with dabrafenib and/or trametinib for eligible patients

  This study is for patients with melanoma, lung cancer, or other solid tumors who have been doing well on dabrafenib and/or trametinib and want to keep getting these treatments without a break.

  Recruiting at 5 sites Phase 4 Novartis · Scottsdale, Arizona and 36 other locations · NCT03340506

Quick answers

How many clinical trials of Trametinib are recruiting right now?

18, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 26 countries. The most sites are in United States (10 trials), China (3 trials), France (3 trials), Austria (2 trials), Denmark (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 8, Phase 1: 3, Phase 1/2: 3, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →